Daily - Go to TTD's Tape of Stock Charts - Monday, March 2, 2015
|
Daily - Go to TTD's Tape of Stock Charts - Monday, March 2, 2015 |
|
Weekly - Bullish Conservative Investors - Go To TTD Long-Term Plays - Monday, March 2, 2015 |
|
Go to Video Show - "How to Make Money With Breakout Stocks" |
|---|
By Leo Fasciocco -- TTD
Ticker Tape Digest presents its daily stock market report containing stocks to go long as breakout trades, quick trades, or bargain trades. We also feature stocks under Significant Accumulation that are poised to breakout.
|
Ticker Tape Digest's Daily schedule guide for TTD subscribers 1. Pre-market - check Breakout Watch List and Quick Trades. 2. Morning - (11:30 - 12 A.M.) - check breakout stocks tape and breakout chart slide show. 3. Midday (1 P.M.) check TTD Midsession Report and see market video show. 4. After close (4 P.M.) check final TTD Report for day. Trading Strategies Bullish Aggressive Investors Bullish - "Breakout Stocks" - ideally suited for bull markets and special situation stocks. Potential for large returns. (See Performance) Aggressive Investor Bullish- "Quick Trade Stocks" -ideally suited for entry into top performing issues looking for a small quick profit." (See Performance) Conservative Investors "Bargain Buy Trades for the Long Term." Ideally suited for entry into top performing big cap stocks on pullbacks within overall up trend.(See Performance) Bearish Aggressive Bearish Investors - "Breakdown Stocks" to Sell Short. Ideally suited for bear markets or market pull backs. Potential for large returns (See Performance) |
|---|
The TTD report also contains stocks to short as breakdown plays and as bargain (swing trade) shorts.
Investors should tend to try to go with a strategy that fits with the stock market's trend, unless there is a special situation play.
TTD's Breakout Stocks - Long are
most suitable for aggressive investors seeking ideal entry points into leading stocks, especially during bull markets. They can do extremely well in bull markets with gains of as much as several hundred percent. 
These stocks can also do extremely well during strong market rallies, or if they are in a industry group that is performing very well. They tend to have strong earnings outlooks and are near new-52 week, or all-time highs.
TTD Quick Trade Stocks - Long These are leading issues that have pulled back in recent days, but could move higher soon. They are most suitable for Aggressive Investors willing to trade short term. These stocks will do extremely well during market advances. They have about 74% win rate. During market rally sequences the win rate is even higher. The return is small 3% to 8% in just a few days.
TTD's Bargain Buy Trades - Long - Long Term. These are for conservative bullish Investors These long-term buys are ideally suited for entry into stocks on pull backs within overall up trend. These stocks can give a good return long-term especially during a bull market.
TTD also presents Stocks To Sell or Sell Short. These issues are suitable for aggressive investors willing to take short positions both as trades or for longer-term plays. These stocks will do very well during bear markets or market pull backs.
TTD's Bearish breakdown stocks to sell short. These issues have potential to fall sharply. They often show a technical breakdown and also some fundamental business problem such as weak earnings.
TTD's multi-media updates include a slide-show that presents charts and analysis at midsession. Some times TTD presents feature analysis on stocks and the market. TTD uses Windows Media Files. (WMV).
TTD also presents a "Breakout Watch List" that is up dated daily. This list consists of key stocks in position to breakout. A close watch of this list can put you in the stock just as it breaks out. A good idea is to study the list and be ready to move into a stock quickly as it hits its breakpoint.
TTD often suggests using stop buy orders to enter. It is very important to buy a breakout stock as close as possible to the breakpoint. The idea is to get "elbow room" if the stock should follow through to the upside. This is very important in being successful in making big money with breakout stocks.
It is also essential to have a stop loss strategy for all stocks in which positions are taken. Not every stock will work as expected. It is important for investors to "police" their portfolios and avoid getting trapped in any bad positions.
Quality rating of breakout Two key factors: 1 - Stock near all-time high in price or near a 52-week high. 2 - earnings growth current year is strong. The ideal play is a stock with an Above Average Quality Rating. The stock is near a new high and will have strong earnings. TTD's other ratings are Average and Below Average.
TTD also has special feature sections on Educational Tips on Investing.
To email Mr. Leo Fasciocco leo@tickertapedigest.com.For service, email Beverly Owen owen@tickertapedigest.com. TTD’s Tel: 1-480-926-1680.
Breakout Stocks
Total Buy Breakouts so far today - 9
Overall Quality of Breakouts - BELOW AVERAGE
Stocks Screened - 8,300
Bull side - Breakout list very selective with some medical and health services stocks pushing higher. Stock market pushes aggressively higher and remains in up trend.
(Put mouse on Dow chart to see Nasdaq chart)
Long Term Environment for bulls: Favorable
Stock Market Momentum
Market (Daily) - NYSE Bullish, Nasdaq Bullish
Market (Weekly) - NYSE Bullish, Nasdaq Bullish
Market (Monthly) - NYSE Bullish, Nasdaq Bullish
Ticker Tape Digest's
|
TTD's Quality Rating of Stock - LGND - AVERAGE |
LGND, based in La Jolla, Ca., develops drugs to treat a variety of diseases such as osteoporosis and Alzheimer. Annual revenues: $65 million. LGND, a small cap play in the strong acting medical sector, breaks out today from a four-month flat base. The move comes with a strong pick up in volume. It was triggered by favorable reports on a drug it could get royalties. 
TTD highlighted LGND as a breakout at our midsession video show on the Web. LGND is trading a heavy 1.2 million shares, four times its average daily volume of 280,000 shares. 
The stock responded to positive developments on Amgen's drug Kyprolis. LGND is poised to get royalties from the drug. Amgen's stock climbed 1.91 to 159.63.
LGND's stock pushed higher in the morning and cleared its breakpoint line. (see 10-minute chart)
The stock continued its advance into the late afternoon peaking intraday at 63.90.
LGND's tape action shows the recent block trades.
One can see the price for the blocks climbing from $55.07 in the prior session to as high as $63.58 Monday.
A key bullish trade came in the morning when a block of 5,000 shares crossed the tape at $59.30.
That was up from the prior block trade at $55.07 on 10,497 shares.
LGND is a biotech firm that develops drugs.
Its late-stage development programs include Promacta, an oral thrombopoietin receptor used to treat adult patients with chronic immune thrombocytopenic purpura.
It also working on Kyprolis to treat multiple myeloma, AVINZA, a pain therapeutic, Captisol-enabled Melphalan IV to treat multiple myeloma transplant setting, Viviant (bazedoxifene) for postmenopausal osteoporosis; and Nexterone, an injectable formulation.
The company's late-stage development programs that are in Phase III clinical trials comprise Captisol-enabled Noxafil-IV; MK-8931 Beta-Secretase Inhibitor program to treat Alzheimer's disease, Captisol-enabled Carbamazepine-IV to manage acute seizure disorder for hospital or emergency settings and Captisol-enabled Delafloxacin-IV to handle acute bacterial skin and skin structure infections.
LGND's 3-year performance chart shows the stock soaring 310% versus a 60% gain for the S&P 500 index.
LGND's long-term chart shows the stock falling to 7 in 2008 due in part to the bear market. The stock was as high as 149 - yes 149 back in 2004. In 2010, the stock had a 1-for-6 reverse stock split. So the high at 149 was adjusted for that change.
Since 2008, LGND advanced strongly hitting a peak of 80.42 in early 2014.
It then pulled back and went into an intermediate-term consolidation.
LGND's daily chart shows the stock rallying from 43 back in October to a peak near 58 by November.
The stock then put down a flat base.
Today's breakout is impressive coming with a widening of the daily spread and a pick up in volume.
LGND's TTD momentum indicator (top of chart) is strongly bullish.
The accumulation - distribution line (bottom of chart) lags a bit but is improving.
Analysts expect LGND to show a 49% surge in earnings for 20154 to $1.48 a share from 99 cents a year ago.
The stock sells with a price-earnings ratio of 41. That is high but okay given the earnings outlook.
Looking out to 2016, the Street projects a 68% jump in net to $2.48 a share from the anticipated $1.48 anticipated for 2015.
However, for the first quarter, analysts expect a 51% decline in profits to 12 cents a share from 25 cents the year before. The highest estimate on the Street is at 15 cents a share.
Going out to the second quarter, earnings are expected to jump 90% to 19 cents a share from 10 cents the year before.
Strategy Opinion: TTD is targeting LGND for a move to 73 off this breakout.
A protective stop can be placed near 59, which is tight.
TTD rates LGND a good intermediate-term play provided earnings meet expectations.
Sponsorship: Excellent. The top two fund holders have a 5-star rating. The have held their positions steady. They are Powershares Dynamic Pharmaceuticals ETF and Fidelity Select Biotechnology Portfolion Fund.
A key fund buyer recently was the 3-star rated Strategic Advisers Small Cap Mid Cap which purchased 41,900 shares. It has a 0.59% stake.
LGND has 19.6 million shares outstanding. Institutions hold 94% of the stock and insiders 1%
Insider Activity: Neutral. Insiders were buyers around $45 in the fourth quarter of last year. They have done some selling around $57.
Currently, 4 analysts follow the stock, 3 have a buy, the same as three months ago. In December, Deutsche Bank put out a buy.
LGND has a book value of $1.34.
Stock Performance Chart with Quarterly Earnings Markers - For Three Years
| TTD's Breakout Profile
Rating Ligand Pharmaceuticals Inc. - (LGND) |
| TTD Check List | Bullish | Bearish | Neutral |
| Near 52-week High | YES | ||
| Volume | YES | ||
| Tick Volume | YES | ||
| Price Trend - Daily | YES | ||
| Price Trend - Long Term | YES | ||
| Price Daily Spread | YES | ||
| Base Structure | YES | ||
| Base - A-D | YES | ||
| Earnings-Quarterly | YES | ||
| Earnings-Long Term | YES | ||
| Earnings Outlook | YES | ||
| Industry Group | YES | ||
| Prior Breakout Success | YES | ||
| Fund Sponsorship | YES | ||
| Total Score | 11 | 2 | 1 |
Charts of Selected Breakout Stocks
| TTD's Quality Rating of Stock - IMKTA - AVERAGE |
| TTD's Quality Rating of Stock - SRCL - AVERAGE |
| TTD's Quality Rating of Stock - HDFC - AVERAGE |
| TTD's Quality Rating of Stock - ATML - AVERAGE |
Ticker Tape Digest’s Daily List of “Stocks To Sell or Sell Short” ranks stocks well timed to be sold immediately based on daily trading. The list can be used as an alert to reduce current long-term positions.
Shorts from tape action so far today - 8
Stocks Screened - 8,300
Long-Term Environment for bears: Unfavorable.
Bear Side - Good number of breakdown stocks. However, Bears be selective. Stock market pushes higher and holds up trend. TTD's short from Friday, Weight Watchers (WTW) at 11.55 falls to 10.50 Monday. Working well for bears.
BIOS, based in Elmsford, N.Y., provides home infusion and home care services. Annual revenues: $1 billion. BIOS's stock falls sharply in heavy trading Monday after the company reported a loss for the quarter. TTD sees more on the downside. 
So far today, BIOS is trading a heavy 6.1 million shares, eight times its average daily volume.
TTD highlighted the stock as a short at our midsession video show on the Web Monday.
BIOS reported a loss from continuing operations for the fourth quarter of 90 cents a share compared with a loss of 23 cents a share a year before.
The company said revenues were up for the quarter, but cited other costs.
BIOS's stock gapped lower in the morning hitting an intraday low of 5. The stock then lifted a bit and trended sideways the rest of the session.
BIOS's tape action shows the recent block trades.
One can see the price for the blocks falling from $6.11 in the prior session to as low s $5.25 Monday.
A key bearish trade came in the morning when a block of 50,000 shares crossed the tape at $5.31. That was down from the prior block trade at $6.11 on 42,849 shares.
BIOS provides home medical care. It works with healthcare payors, pharmaceutical firms, government agencies, physicians, and patients.
This year, analysts are forecasting BIOS will show a loss of 5 cents a share. For the upcoming first quarter they see a loss of 4 cents a share.
BIOS's daily chart shows the stock cutting below key support with big volume. The TTD momentum indicator (top of chart) is now bearish.
Strategy Opinion: TTD is targeting BIOS for a decline to 3.90 within the next few months, or sooner. A protective stop buy can be placed near 5.70.
| TTD's Quality Rating of Stock - BIOS - BELOW AVERAGE |
TTD columnist Leo Fasciocco has covered the stock market for over 20 years. His articles appear in many publications. He is also a speaker at the Intershow conferences. He has been on television and radio. He is author of many educational articles about stock investing and the book “Guide To High-Performance Investing.”
For information to subscribe to the Ticker Tape Digest Services call: Beverly Owen at 1-480-926-1680. Distributed by Corona Publishing Enterprises. Ticker Tape Digest Inc. P.O. Box 2044 Chandler, Az. 85244-2044. TTD “Professional Report” is available on the World Wide Web: $100 per month. Password needed. “TTD Professional“ Faxed is $200 per month. The TTD Daily Report is $39.95. Credit cards accepted.
(The information contained has been prepared from data deemed reliable but there is no guarantee of complete accuracy. Ticker Tape Digest Inc. is not affiliated with any broker, dealer or investment advisor. Nothing in this publication constitutes an offer, recommendation or solicitation to buy or sell any securities. Further research is advised. This report is copyrighted and no redistribution is permitted with out permission.)
